FDA Approves Elitek For Management Of Plasma Uric Acid Levels In Adults With Leukemia, Lymphoma, And Solid Tumors Receiving Anti-Cancer Therapy

Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.